Kidney/Renal Cancer
Show Only Open Trials
1.
A Phase 1a/b Non-Randomized, Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Sterile Compound 31510 (Ubidecarenone, USP) Nanosuspension for Injection Administered Intravenously to Patients with Solid Tumors
- Study Status: Open to Enrollment
- Sponsor: Berg Pharma
- Disease Status and/or Stage: Advanced Solid Tumors
2.
A Randomized, Open-Label, Phase 3 Study of BMS-936558 vs Everolimus in Subjects with Advanced or Metastatic Clear-Cell Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy
- Study Status: Open to Enrollment
- Sponsor: Bristol-Myers Squibb
- Disease Status and/or Stage: Advanced or Metastatic Kidney Cancer
- Protocol ID: BMS CA209-025-041
3.
A randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy and safety of pazopanib as adjuvant therapy for subjects with localized or locally advanced RCC following nephrectomy
- Study Status: Open to Enrollment
- Sponsor: GlaxoSmithKline
- Disease Status and/or Stage: Kidney Cancer, Surgically Removed
4.
A Phase I/II Study of Vorinostat in Combination with Isotretinoin in the Treatment of Patients with Advanced Renal Cell Carcinoma
- Study Status: Closed to Enrollment
- Sponsor: Weill Cornell Medical College, National Cancer Institute
- Disease Status and/or Stage: Metastatic or Advanced Kidney Cancer
5.
A Phase I/II Trial of BAY 43-9006 plus Gemcitabine and Capecitabine in the Treatment of Patients with Advanced Renal Cell Carcinoma
- Study Status: Closed to Enrollment
- Sponsor: Weill Cornell Medical College, National Cancer Institute
- Disease Status and/or Stage: Advanced, Unresectable and/or Metastatic Kidney Cancer
6.
ECOG 2805: A Randomized, Double-Blind Phase III Trial of Adjuvant Sunitinib versus Sorafenib versus Placebo in Patients with Resected Renal Cell Carcinoma (RCC)
- Study Status: Closed to Enrollment
- Sponsor: Eastern Cooperative Oncology Group
- Disease Status and/or Stage: Renal Cell Cancer
7.
A Phase I Study of 177Lu Radiolabeled Monoclonal Antibody HuJ591-GS (177Lu-591) in Patients with Nonprostate Metastatic Solid Tumors: A Pilot Study
- Study Status: Open to Enrollment
- Sponsor: Weill Cornell Medical College
- Disease Status and/or Stage: Metastatic Solid Tumor
